Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COMPUGROUP MEDICAL SE & CO. KGAA

(COP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CompuGroup Medical SE & Co. KGaA announces medium-term targets for EBITDA-margin for the first time

09/14/2021 | 10:46am EDT

DGAP-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Forecast CompuGroup Medical SE & Co. KGaA announces medium-term targets for EBITDA-margin for the first time 14-Sep-2021 / 16:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

CompuGroup Medical SE & Co. KGaA ("CompuGroup Medical") announces medium-term targets for the development of the adjusted EBITDA-margin for the first time. The medium-term growth target of increasing group revenues year-on-year organically by 5 percent and more per year from 2021 through 2025 had been published previously. In addition, today the managing directors of the general partner CompuGroup Medical Management SE ("Managing Directors") have also concluded and adopted specific targets from the ongoing planning process with regard to the medium-term increase in adjusted EBITDA-margin for the first time. Accordingly, CompuGroup Medical aims to increase the adjusted EBITDA margin to approximately 25 % in 2023 and approximately 27 % in 2025. Further information on medium-term targets will be presented at tomorrow's virtual Capital Markets Day.

In light of the ongoing investment program announced in December 2020 to accelerate growth, the Managing Directors confirm the full year 2021 guidance. CompuGroup Medical expects revenues in 2021 to be in a range of EUR 1 billion and EUR 1.04 billion as well as adjusted EBITDA between EUR 210 million and EUR 230 million.

Explanation of financial figures:

The financial figure of adjusted operating profit (adjusted EBITDA) is not a figure defined in accordance with International Financial Reporting Standards (IFRS). It includes earnings before interest, taxes, depreciation and amortization, adjusted by the effects of major acquisitions and disposals of subsidiaries, business units and shareholdings, amortization as well as write-ups of shareholdings, effects from the acquisition, construction and sale of real estate, amortization and write-ups on owner-occupied real estate as well as expenses in connection with share-based compensation programs of the Managing Directors, as well as other non-operating or non-period-related non-recurring effects.

Adjusted EBITDA-margin is calculated by dividing adjusted EBITDA by group revenue.

Forward-Looking Statements

This release contains "forward-looking statements". Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's ("CompuGroup Medical") current view on future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical as well as their affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons. Any responsibility for the future accuracy of the forward-looking statements expressed in this release or the actual occurrence of the forecast developments is expressly excluded.

-----------------------------------------------------------------------------------------------------------------------

14-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      CompuGroup Medical SE & Co. KGaA 
              Maria Trost 21 
              56070 Koblenz 
              Germany 
Phone:        +49 (0)261 8000 7030 
Fax:          +49 (0)261 8000 3200 
E-mail:       investor@cgm.com 
Internet:     www.cgm.com 
ISIN:         DE000A288904 
WKN:          A28890 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1233329 
 
End of Announcement  DGAP News Service 
=------------ 

1233329 14-Sep-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1233329&application_name=news

(END) Dow Jones Newswires

September 14, 2021 10:45 ET (14:45 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
COMPUGROUP MEDICAL SE & CO. KGAA 0.84% 72.25 Delayed Quote.-8.84%
UNITED PARCEL SERVICE INC -0.07% 193.57 Delayed Quote.15.08%
All news about COMPUGROUP MEDICAL SE & CO. KGAA
10/15COMPUGROUP MEDICAL : Kepler Cheuvreux sticks Neutral
MD
10/06COMPUGROUP MEDICAL : Raised to Buy by Warburg Research
MD
09/21COMPUGROUP MEDICAL SE & CO. KGAA : Preliminary announcement of the publication of quarterl..
EQ
09/20COMPUGROUP MEDICAL : Deutsche Bank remains its Buy rating
MD
09/16COMPUGROUP MEDICAL : Warburg Research revises his opinion and turns to Neutral
MD
09/15COMPUGROUP MEDICAL : Receives a Sell rating from Baader Bank
MD
09/15COMPUGROUP MEDICAL : Receives a Buy rating from Warburg Research
MD
09/15COMPUGROUP MEDICAL : Gets a Sell rating from Baader Bank
MD
09/14COMPUGROUP MEDICAL : Receives a Buy rating from Jefferies
MD
09/14COMPUGROUP MEDICAL :  Medical announces medium-term targets for EBITDA-margin for the firs..
PU
More news
Analyst Recommendations on COMPUGROUP MEDICAL SE & CO. KGAA
More recommendations
Financials
Sales 2021 1 021 M 1 189 M 1 189 M
Net income 2021 81,8 M 95,2 M 95,2 M
Net Debt 2021 504 M 586 M 586 M
P/E ratio 2021 47,1x
Yield 2021 0,79%
Capitalization 3 778 M 4 397 M 4 397 M
EV / Sales 2021 4,19x
EV / Sales 2022 3,89x
Nbr of Employees 8 030
Free-Float 48,8%
Chart COMPUGROUP MEDICAL SE & CO. KGAA
Duration : Period :
CompuGroup Medical SE & Co. KGaA Technical Analysis Chart | COP | DE000A288904 | MarketScreener
Technical analysis trends COMPUGROUP MEDICAL SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 71,65 €
Average target price 84,30 €
Spread / Average Target 17,7%
EPS Revisions
Managers and Directors
Dirk Wössner Chairman-Management Board & CEO
Michael Rauch Chief Financial Officer
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Sven Thomas Müller Vice Chairman & Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
COMPUGROUP MEDICAL SE & CO. KGAA-8.84%4 397
ORACLE CORPORATION49.19%265 332
SAP SE16.34%171 213
SERVICENOW, INC.23.59%134 781
DOCUSIGN, INC.22.76%53 682
CONSTELLATION SOFTWARE INC.33.20%37 773